About Ganga Pharmaceuticals
Ganga Pharmaceuticals is a publicly listed company based in Mumbai (India) founded in 1989 by Bharat Sharma. Its Indian entity Ganga Pharmaceuticals Ltd reported revenue of ₹3.11 Cr. Ganga Pharmaceuticals offers products and services including Ayurvedic Medicines and Antacid and Digestive Products. Its focus areas include Traditional Nutraceuticals, Diversified, Herbal and Alternative Medicine Products.
Company details
Provider of local news and information. It delivers up-to-date reporting on local events, including news, sports, and lifestyle features. The platform also includes sections dedicated to opinion pieces, classifieds, and an e-edition. Content covers a range of topics relevant to the local community, aiming to keep residents informed about current affairs and community happenings. The platform offers a mix of text, images, and video content.
- Headquarters Mumbai, India
- Founders Bharat Sharma
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ayurvedganga.com
- Social LinkedIn Facebook
- Legal Name Ganga Pharmaceuticals Ltd.
- Market Cap₹7.39 Cr
GANGAPHARM · BSE
- Share Price₹12.50
0.00% today
- Revenue₹2.83 Cr
FY 2025-26 · +7.2% YoY
- EBITDA₹0.05 Cr
Margin 1.8%
- Net Profit₹0.11 Cr
FY 2025-26 · +37.5% YoY
- P/E (TTM)485.8x
P/B 1.8x
- ROE1.3%
ROCE 2.9%
- Debt / Equity0.16
Interest cover -1,300.0x
Associated legal entities of Ganga Pharmaceuticals
Ganga Pharmaceuticals operates through Ganga Pharmaceuticals Ltd, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ganga Pharmaceuticals Ltd Listed CIN L99999MH1989PLC053392 | Active | 11 Sep 1989 | Palghar, Maharashtra | ₹3.1 Cr | 16 | 8 | View details |
Products & Services of Ganga Pharmaceuticals
Ganga Pharmaceuticals offers a comprehensive portfolio of products and services, including Ayurvedic Medicines and Antacid and Digestive Products.
Ayurvedic medicines are manufactured for relief from various ailments including digestive issues and hair problems
Antacid and digestive products are produced to provide prompt relief from acidity and constipation
Board of directors of Ganga Pharmaceuticals Ltd (Ganga Pharmaceuticals)
Ganga Pharmaceuticals Ltd is the primary company behind Ganga Pharmaceuticals. The board of Ganga Pharmaceuticals Ltd currently have 5 directors; the longest-serving is Bharat Brijmohan Sharma, appointed in 1989. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Bharat Brijmohan Sharma DIN 00077026 | Managing Director | 11 Sep 1989 | 37 yrs 1 mo | Ganga Pharmaceuticals Ltd |
| Sanjay Vyankatesh Kulkarni DIN 00065190 | Director | 01 Apr 2012 | 14 yrs 7 mo | Ganga Pharmaceuticals Ltd |
| Srijna Sharma DIN 00078169 | Whole-time director | 01 Apr 2012 | 14 yrs 7 mo | Ganga Pharmaceuticals Ltd |
| Munna Baijnath Chaurasia DIN 10977965 | Director | 27 Mar 2025 | 1 yr 7 mo | Ganga Pharmaceuticals Ltd |
| Aman Mukesh Chaudhari DIN 10979664 | Director | 27 Mar 2025 | 1 yr 7 mo | Ganga Pharmaceuticals Ltd |
People of Ganga Pharmaceuticals
1 people are tracked at Ganga Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder & MD | Leadership |
Complete people profiles for Ganga Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ganga Pharmaceuticals
Ganga Pharmaceuticals is a publicly listed company on the BSE with ticker symbol GANGAPHARM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Feb 2016
- Listed onBSE: 539680
- Listed entityGanga Pharmaceuticals Ltd.
- Exchange sectorHealth technology
- ISININE615T01017
- Share price₹12.00 · 2026-05-11
- Volume (last session)8,000
- Analyst consensusNo rating
Financials of Ganga Pharmaceuticals
Exchange-reported figures of Ganga Pharmaceuticals Ltd, the listed company behind Ganga Pharmaceuticals (BSE: GANGAPHARM).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2.83 | 2.64 | 2.74 | 2.59 | 2.49 | 2.37 | 3.08 |
| Revenue growth | +7.2% | -3.7% | +5.8% | +4.0% | +5.1% | -23.1% | - |
| EBITDA | 0.05 | (0.12) | 0.06 | 0.00 | 0.05 | 0.03 | 0.38 |
| EBITDA margin | +1.8% | -4.6% | +2.2% | 0.0% | +2.0% | +1.3% | +12.3% |
| Profit before tax | 0.14 | 0.09 | 0.07 | 0.05 | 0.07 | 0.04 | 0.26 |
| Net profit | 0.11 | 0.08 | 0.05 | 0.03 | 0.06 | 0.02 | 0.20 |
| Net profit margin | +3.9% | +3.0% | +1.8% | +1.2% | +2.4% | +0.8% | +6.5% |
| EPS (₹) | 0.17 | 0.16 | 0.10 | 0.10 | 0.09 | 0.05 | 0.46 |
| Balance sheet | |||||||
| Total assets | 9.40 | 8.55 | 8.41 | 7.28 | 7.34 | 7.10 | 6.83 |
| Net worth | 8.31 | 7.13 | 7.05 | 5.45 | 5.41 | 5.37 | 5.35 |
| Total debt | 1.09 | 1.42 | 1.36 | 1.83 | 1.93 | 1.73 | 1.47 |
| Cash & bank | 0.06 | 0.30 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 |
| Net working capital | 7.32 | 6.46 | 5.51 | 4.44 | 4.27 | 4.03 | 3.69 |
| Cash flow | |||||||
| Cash from operations | (1.31) | (0.58) | (1.26) | (0.04) | (0.21) | (0.18) | (0.31) |
| Cash from investing | 0.24 | 1.18 | 0.13 | 0.49 | 0.19 | 0.28 | 0.37 |
| Cash from financing | 0.82 | (0.33) | 1.14 | (0.44) | 0.03 | (0.10) | (0.29) |
| Particulars | Jun 2024 |
|---|---|
| Revenue | 0.00 |
| Other income | 0.00 |
| Total expenses | 0.00 |
| EBITDA | 0.00 |
| Depreciation | 0.00 |
| Interest | 0.00 |
| Profit before tax | 0.00 |
| Tax | 0.00 |
Financial Statements
| Particulars | Jun 2024 |
|---|---|
| Revenue | 0.00 |
| Other income | 0.00 |
| Total expenses | 0.00 |
| EBITDA | 0.00 |
| Depreciation | 0.00 |
| Interest | 0.00 |
| Profit before tax | 0.00 |
| Tax | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.83 | 2.64 | 2.74 | 2.59 | 2.49 | 2.37 | 3.08 |
| Revenue growth | +7.2% | -3.7% | +5.8% | +4.0% | +5.1% | -23.1% | - |
| Other income | 0.28 | 0.44 | 0.24 | 0.30 | 0.26 | 0.25 | 0.17 |
| Total expenses | 2.78 | 2.76 | 2.68 | 2.59 | 2.44 | 2.34 | 2.70 |
| Employee cost | 0.25 | 0.18 | 0.18 | 0.18 | 0.04 | 0.03 | 0.05 |
| EBITDA | 0.05 | (0.12) | 0.06 | 0.00 | 0.05 | 0.03 | 0.38 |
| EBITDA margin | +1.8% | -4.6% | +2.2% | 0.0% | +2.0% | +1.3% | +12.3% |
| Depreciation | 0.06 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 |
| Interest | 0.13 | 0.18 | 0.18 | 0.19 | 0.19 | 0.19 | 0.24 |
| Profit before tax | 0.14 | 0.09 | 0.07 | 0.05 | 0.07 | 0.04 | 0.26 |
| Tax | 0.03 | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 | 0.06 |
| Net profit | 0.11 | 0.08 | 0.05 | 0.03 | 0.06 | 0.02 | 0.20 |
| Net profit margin | +3.9% | +3.0% | +1.8% | +1.2% | +2.4% | +0.8% | +6.5% |
| EPS (₹) | 0.17 | 0.16 | 0.10 | 0.10 | 0.09 | 0.05 | 0.46 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.91 | 4.84 | 4.84 | 4.06 | 4.06 | 4.06 | 4.06 |
| Reserves & surplus | 2.40 | 1.67 | 1.59 | 1.39 | 1.35 | 1.31 | 1.29 |
| Shareholders' funds (net worth) | 8.31 | 7.13 | 7.05 | 5.45 | 5.41 | 5.37 | 5.35 |
| Secured loans | 0.87 | 1.01 | 0.76 | 1.02 | 1.01 | 1.51 | 1.26 |
| Unsecured loans | 0.22 | 0.41 | 0.60 | 0.81 | 0.92 | 0.22 | 0.21 |
| Total debt | 1.09 | 1.42 | 1.36 | 1.83 | 1.93 | 1.73 | 1.47 |
| Total liabilities | - | - | 8.41 | 7.28 | 7.34 | 7.10 | 6.83 |
| Assets | |||||||
| Gross block | 1.50 | 1.47 | 1.37 | 1.35 | 1.33 | 1.32 | 1.30 |
| Net block | 0.64 | 0.67 | 0.61 | 0.64 | 0.68 | 0.72 | 0.76 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 |
| Inventories | 1.17 | 1.18 | 1.24 | 1.18 | 1.15 | 1.13 | 1.04 |
| Sundry debtors | 0.94 | 0.91 | 0.92 | 0.89 | 0.89 | 0.82 | 1.07 |
| Cash & bank balances | 0.06 | 0.30 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 |
| Loans & advances | 5.40 | 4.47 | 3.56 | 3.05 | 2.85 | 2.62 | 2.30 |
| Total current assets | 7.57 | 6.86 | 5.75 | 5.15 | 4.91 | 4.58 | 4.42 |
| Total current liabilities | 0.25 | 0.40 | 0.24 | 0.71 | 0.64 | 0.55 | 0.73 |
| Net working capital | 7.32 | 6.46 | 5.51 | 4.44 | 4.27 | 4.03 | 3.69 |
| Total assets | 9.40 | 8.55 | 8.41 | 7.28 | 7.34 | 7.10 | 6.83 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.30 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.24 |
| Net cash from operating activities | (1.31) | (0.58) | (1.26) | (0.04) | (0.21) | (0.18) | (0.31) |
| Net cash from investing activities | 0.24 | 1.18 | 0.13 | 0.49 | 0.19 | 0.28 | 0.37 |
| Net cash from financing activities | 0.82 | (0.33) | 1.14 | (0.44) | 0.03 | (0.10) | (0.29) |
| Net change in cash | (0.24) | 0.27 | 0.00 | 0.01 | 0.01 | 0.00 | (0.22) |
| Closing cash | 0.06 | 0.30 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +7.2% | -3.7% | +5.8% | +4.0% | +5.1% | -23.1% | - |
| EBITDA growth | +141.7% | -300.0% | - | -100.0% | +66.7% | -92.1% | - |
| PBT growth | +55.6% | +28.6% | +40.0% | -28.6% | +75.0% | -84.6% | 0.0% |
| Net income growth | +37.5% | +60.0% | +66.7% | -50.0% | +200.0% | -90.0% | - |
| Revenue CAGR (3Y) | +3.0% | +2.0% | +5.0% | -5.6% | -9.5% | -8.1% | +0.8% |
| EBITDA CAGR (3Y) | - | - | +26.0% | -100.0% | -50.8% | -54.6% | +8.2% |
| Profitability & leverage | |||||||
| Net income margin | +3.9% | +3.0% | +1.8% | +1.2% | +2.4% | +0.8% | +6.5% |
| Return on capital employed | +2.9% | +3.3% | +3.2% | +3.3% | +3.3% | +3.3% | +7.2% |
| Return on net worth | +1.3% | +1.1% | +0.8% | +0.7% | +0.7% | +0.4% | +3.6% |
| Debt / equity | 0.16 | 0.20 | 0.25 | 0.35 | 0.34 | 0.30 | 0.32 |
| Long-term debt / equity | 0.02 | 0.04 | 0.08 | 0.14 | 0.15 | 0.12 | 0.12 |
| Interest cover | -1,300.00 | -105.88 | 1,800.00 | -316.67 | - | -950.00 | 72.73 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.91 | 1.86 | 2.01 | 1.93 | 1.88 | 1.81 | 2.38 |
| Inventory turnover | 2.41 | 2.18 | 2.26 | 2.22 | 2.18 | 2.18 | 2.81 |
| Debtors turnover | 3.06 | 2.89 | 3.03 | 2.91 | 2.91 | 2.51 | 2.68 |
| EPS (₹) | 0.17 | 0.16 | 0.10 | 0.10 | 0.09 | 0.05 | 0.46 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 14.06 | 13.46 | 13.30 | 13.42 | 13.32 | 13.23 | 13.18 |
Top companies in Alternative Medicine Products
3 companies that operate in the same segment as Ganga Pharmaceuticals (Alternative Medicine Products) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Homeopathic medicine manufacturing and online retail in India. | 1898 | Noida, Uttar Pradesh, India | USD 26.35 M | 1,192 | ||
Operates an online store specializing in ayurvedic and homeopathic medicines. | 2016 | Delhi, Delhi, India | USD 1.25 M | 16 | ||
Offers Ayurvedic treatments, consultations, and products for various diseases and wellness. | 1992 | Faridabad, Haryana, India | USD 10.08 M | 570 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ganga Pharmaceuticals
Complete news archive for Ganga Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ganga Pharmaceuticals
Ganga Pharmaceuticals was founded in 1989.
Ganga Pharmaceuticals is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
The primary company behind Ganga Pharmaceuticals, Ganga Pharmaceuticals Ltd, reported revenue of ₹3.11 Cr for FY 2026, up 7% year on year.
Provider of local news and information. It delivers up-to-date reporting on local events, including news, sports, and lifestyle features. The platform also includes sections dedicated to opinion pieces, classifieds, and an e-edition. Content covers a range of topics relevant to the local community, aiming to keep residents informed about current affairs and community happenings. The platform offers a mix of text, images, and video content.
Ganga Pharmaceuticals offers Ayurvedic Medicines and Antacid and Digestive Products.
Yes, Ganga Pharmaceuticals is publicly traded on BSE under the ticker symbol GANGAPHARM.
Ganga Pharmaceuticals operates through Ganga Pharmaceuticals Ltd.
The legal entities of Ganga Pharmaceuticals currently have 7 directors, including Bharat Brijmohan Sharma, Sanjay Vyankatesh Kulkarni, Srijna Sharma and others.